Home › Compare › ATONY vs ABBV
ATONY yields 2.61% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ATONY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ATONY + ABBV for your $10,000?
Anton Oilfield Services Group, an investment holding company, provides oilfield engineering and technical services for oil companies in the People's Republic of China and internationally. It operates through four segments: Inspection Services, Oilfield Management Services, Oilfield Technical Services, and Drilling Rig Services. The company offers inspection and repair, intelligent monitoring, and digital and intelligent management services of various equipment and facilities for the operation of customers' oil and gas field equipment, facilities, and assets; management general contracting, including reservoir support, operation management, production operation, logistics, and third-party service provider management, as well as health, safety, and environment services; capacity construction; oilfield development management; and oilfield operation and maintenance services, such as engineering contracting, commissioning, and operation and maintenance management services for oilfield assets of oil companies. It also provides geological, drilling, well completion, and stimulation technology services, as well as asset leasing services; and drilling and well workover services that require drilling rigs. In addition, the company manufactures rod casings; and provides construction services. Anton Oilfield Services Group was founded in 1999 and is based in Beijing, China. Anton Oilfield Services Group is a subsidiary of Pro Development Holdings Corp.
Full ATONY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.